Eyenovia (EYEN) Revenue & Revenue Breakdown
Eyenovia Revenue Highlights
Latest Revenue (Y)
$3.79K
Latest Revenue (Q)
$4.99K
Eyenovia Revenue by Period
Eyenovia Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $3.79K | 100.00% |
| 2022-12-31 | - | -100.00% |
| 2021-12-31 | $14.00M | 600.00% |
| 2020-12-31 | $2.00M | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2015-12-31 | - | - |
Eyenovia generated $3.79K in revenue during NA 2023, up 100.00% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Eyenovia Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $4.99K | 92.85% |
| 2023-12-31 | $2.59K | 116.11% |
| 2023-09-30 | $1.20K | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | -100.00% |
| 2021-12-31 | $10.00M | 100.00% |
| 2021-09-30 | - | -100.00% |
| 2021-06-30 | $2.00M | - |
| 2021-03-31 | $2.00M | - |
| 2020-12-31 | $2.00M | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | 100.00% |
| 2016-12-31 | - | - |
Eyenovia generated $4.99K in revenue during Q1 2024, up 92.85% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Eyenovia Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| MCRB | Seres Therapeutics | $126.33M | - |
| ARDX | Ardelyx | $124.46M | $73.22M |
| CDTX | Cidara Therapeutics | $63.91M | $8.46M |
| FBIO | Fortress Biotech | $59.66M | $13.03M |
| OCUL | Ocular Therapeutix | $58.44M | $14.71M |
| BLRX | BioLineRx | $4.80M | $6.86M |
| IMMP | Immutep | $3.51M | $2.11M |
| LXRX | Lexicon Pharmaceuticals | $1.20M | $1.65M |
| IBRX | ImmunityBio | $622.00K | $1.05M |
| EYEN | Eyenovia | $3.79K | $4.99K |
| RVPH | Reviva Pharmaceuticals | - | - |
| SELB | Cartesian Therapeutics | - | $6.55M |
| INZY | Inozyme Pharma | - | - |
| CGTX | Cognition Therapeutics | - | - |
| DRTS | Alpha Tau Medical | - | - |
| KOD | Kodiak Sciences | - | - |
| AVXL | Anavex Life Sciences | - | - |
| GLSI | Greenwich LifeSciences | - | - |
| RNAZ | TransCode Therapeutics | - | - |
| TNYA | Tenaya Therapeutics | - | - |
EYEN Revenue FAQ
What is Eyenovia’s yearly revenue?
Eyenovia's yearly revenue for 2023 was $3.79K, representing an increase of 100.00% compared to 2022. The company's yearly revenue for 2022 was $0, representing a decrease of -100.00% compared to 2021. EYEN's yearly revenue for 2021 was $14M, representing an increase of 600.00% compared to 2020.
What is Eyenovia’s quarterly revenue?
Eyenovia's quarterly revenue for Q1 2024 was $4.99K, a 92.85% increase from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $2.59K, a 116.11% increase from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022). EYEN's quarterly revenue for Q3 2023 was $1.2K, a 100.00% increase from the previous quarter (Q2 2023), and a 0% increase year-over-year (Q3 2022).
What is Eyenovia’s revenue growth rate?
Eyenovia's revenue growth rate for the last 3 years (2021-2023) was -99.97%, and for the last 5 years (2019-2023) was 0%.